PAX8 and neoplasm: Using NIH-OVCAR3 cells bearing doxycycline-inducible shRNAs against PAX8 or MECOM confirmed that PAX8 silencing leads to profound regression (Fig. 4B), while MECOM loss induces tumor growth arrest/stasis (Fig. 4C).